GlassScriptPhysician profile
Pranitha Naini
NPI 1003959974
$7,530.12
in general payments reported to CMS, 2019-2025
40 companies · $3,820 in 2025
The $3,820 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2022: $19.68 · 2023: $567 · 2024: $3,111 · 2025: $3,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,753 · Consulting Fee: $2,426 · Long Term Medical Supply Or Device Loan: $299 · Education: $20.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,753.41 |
| Consulting Fee | $2,425.50 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $20.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,981.89 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $1,026.75 | 2023-2025 | |
| Genzyme Corporation | $903.40 | 2024-2025 | |
| Janssen Biotech, INC. | $629.08 | 2023-2025 | Rybrevant, Carvykti, Erleada |
| Astrazeneca Pharmaceuticals LP | $374.81 | 2023-2025 | Calquence, Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $212.95 | 2024-2025 | Keytruda, Lynparza |
| Abbvie INC. | $194.76 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $167.77 | 2023-2025 | Opdivo, Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $158.75 | 2024-2025 | Iclusig, Ninlaro |
| Gilead Sciences, INC. | $149.83 | 2021-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $144.11 | 2023-2024 | Rezlidhia, Tavalisse |
| Caris Mpi, INC. | $124.67 | 2025 | Mi Cancer Seek |
| Karyopharm Therapeutics INC. | $116.19 | 2023 | Xpovio |
| Eisai INC. | $114.62 | 2024-2025 | |
| Genmab U.S., INC. | $97.86 | 2025 | Epkinly |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $95.62 | 2024-2025 | Polivy, Tecentriq, Lunsumio |
| Sobi, INC | $88.07 | 2024-2025 | |
| Tersera Therapeutics LLC | $82.59 | 2024-2025 | Quzyttir, Xermelo |
| Beone Medicines USA, INC. | $76.39 | 2025 | Brukinsa, Tevimbra |
| Pfizer INC. | $75.60 | 2025 | |
| Lilly USA, LLC | $66.59 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Myriad Genetic Laboratories, INC. | $65.04 | 2023-2025 | Myrisk |
| Pharmaessentia USA Corporation | $64.98 | 2024-2025 | Besremi |
| Glaxosmithkline, LLC. | $50.70 | 2024-2025 | Blenrep, Ojjaara |
| Exelixis INC. | $49.50 | 2024-2025 | Cabometyx |
| Adaptive Biotechnologies Corporation | $48.89 | 2023-2025 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $48.15 | 2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $37.10 | 2024-2025 | Xarelto |
| Array Biopharma INC | $36.51 | 2025 | Mektovi, Braftovi, Tukysa |
| Alnylam Pharmaceuticals INC. | $33.77 | 2024-2025 | Givlaari |
| Astellas Pharma US INC | $28.67 | 2024 | Padcev |
| Invivyd INC | $28.17 | 2025 | Pemgarda |
| Beigene USA, INC. | $24.92 | 2024 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $22.19 | 2024 | Qinlock |
| Incyte Corporation | $20.75 | 2024 | Jakafi |
| Teleflex LLC | $19.68 | 2022 | |
| Agios Pharmaceuticals, INC. | $19.07 | 2024 | Pyrukynd |
| Acrotech Biopharma INC. | $18.21 | 2025 | Beleodaq |
| Bayer Healthcare Pharmaceuticals INC. | $16.28 | 2024 | |
| Pharmacosmos Therapeutics INC. | $15.24 | 2024 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranitha Naini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.